-$0.21 Earnings Per Share Expected for Lexicon Pharmaceuticals, Inc. (LXRX) This Quarter
Wall Street brokerages expect Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) to announce earnings per share (EPS) of ($0.21) for the current quarter, Zacks reports. Three analysts have issued estimates for Lexicon Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.24) and the highest estimate coming in at ($0.18). Lexicon Pharmaceuticals reported earnings of ($0.40) per share during the same quarter last year, which indicates a positive year over year growth rate of 47.5%. The firm is scheduled to report its next earnings report on Thursday, May 2nd.
According to Zacks, analysts expect that Lexicon Pharmaceuticals will report full year earnings of ($0.59) per share for the current year, with EPS estimates ranging from ($0.95) to $0.23. For the next financial year, analysts forecast that the company will report earnings of ($0.72) per share, with EPS estimates ranging from ($1.60) to ($0.05). Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Lexicon Pharmaceuticals.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings results on Wednesday, March 13th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.12. Lexicon Pharmaceuticals had a negative return on equity of 911.43% and a negative net margin of 192.53%. The firm had revenue of $17.10 million for the quarter, compared to analyst estimates of $13.33 million. During the same period last year, the company earned ($0.27) EPS. The firm’s quarterly revenue was down 49.7% on a year-over-year basis.
Several institutional investors and hedge funds have recently bought and sold shares of the company. CWM Advisors LLC raised its stake in shares of Lexicon Pharmaceuticals by 30.2% in the 4th quarter. CWM Advisors LLC now owns 13,059 shares of the biopharmaceutical company’s stock worth $87,000 after buying an additional 3,030 shares in the last quarter. Pegasus Asset Management Inc. bought a new stake in shares of Lexicon Pharmaceuticals in the 4th quarter worth $66,000. Paloma Partners Management Co bought a new stake in shares of Lexicon Pharmaceuticals in the 4th quarter worth $73,000. MetLife Investment Advisors LLC raised its stake in shares of Lexicon Pharmaceuticals by 49.8% in the 3rd quarter. MetLife Investment Advisors LLC now owns 35,705 shares of the biopharmaceutical company’s stock worth $381,000 after buying an additional 11,862 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY raised its stake in shares of Lexicon Pharmaceuticals by 409.3% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 14,760 shares of the biopharmaceutical company’s stock worth $98,000 after buying an additional 11,862 shares in the last quarter. 99.16% of the stock is currently owned by institutional investors.
NASDAQ:LXRX traded down $0.08 during mid-day trading on Friday, reaching $5.58. The company’s stock had a trading volume of 645,697 shares, compared to its average volume of 906,341. Lexicon Pharmaceuticals has a twelve month low of $4.25 and a twelve month high of $13.97. The firm has a market cap of $611.06 million, a price-to-earnings ratio of -4.90 and a beta of 0.71.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Featured Article: Yield Curve
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.